REGENXBIO Inc. (RGNX) Stock Price

RGNXStock

$9.66+7.21%52W

Market Cap$637.69M

P/E—

PEG Ratio—

Div yield—

Beta1.09

RGNX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)7.62%

Price vs S&P 500 (4W)-4.55%

VGM Score62.62

Book Value / Share (Quarterly)$1.32

P/TBV (Annual)1.66x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)14.78%

Cash Flow / Share (Quarterly)$-4.61

Price vs S&P 500 (YTD)-45.74%

Gross Margin (TTM)86.38%

Net Profit Margin (TTM)-112.58%

EPS (TTM)$-3.79

10-Day Avg Trading Volume1.58M

EPS Excl Extra (TTM)$-3.79

Revenue Growth (5Y)1.97%

EPS (Annual)$-3.76

ROI (Annual)-66.91%

Gross Margin (Annual)88.09%

Net Profit Margin (5Y Avg)-179.96%

Cash / Share (Quarterly)$1.95

Revenue Growth QoQ (YoY)405.73%

ROA (Last FY)-42.80%

Revenue Growth TTM (YoY)12.00%

EBITD / Share (TTM)$-2.85

ROE (5Y Avg)-79.66%

Operating Margin (TTM)-94.08%

Cash Flow / Share (Annual)$-2.48

P/B Ratio9.78x

P/B Ratio (Quarterly)8.63x

Net Income / Employee (Annual)$-522,600

EV / Revenue (TTM)4.85x

Net Interest Coverage (TTM)-4.91x

ROA (TTM)-46.04%

EV / EBITDA (TTM)7.06x

EPS Incl Extra (Annual)$-3.76

Current Ratio (Annual)2.38x

Quick Ratio (Quarterly)2.71x

3-Month Avg Trading Volume1.90M

52-Week Price Return7.21%

Revenue / Employee (TTM)$470,300

Tangible BV / Share (Quarterly)$8.25

P/S Ratio (Annual)4.12x

Asset Turnover (Annual)0.38x

52-Week High$16.19

Operating Margin (5Y Avg)-174.20%

EPS Excl Extra (Annual)$-3.76

CapEx CAGR (5Y)-38.26%

Tangible BV CAGR (5Y)23.04%

26-Week Price Return19.55%

Quick Ratio (Annual)2.28x

13-Week Price Return40.20%

Total Debt / Equity (Annual)1.82x

Current Ratio (Quarterly)2.86x

Enterprise Value$846.74M

Revenue / Share Growth (5Y)-4.43%

Asset Turnover (TTM)0.41x

Book Value / Share Growth (5Y)-27.50%

Revenue / Employee (Annual)$459,400

Pretax Margin (Annual)-113.75%

Cash / Share (Annual)$4.52

3-Month Return Std Dev106.25%

Gross Margin (5Y Avg)69.44%

Net Income / Employee (TTM)$-529,500

ROE (Last FY)-188.72%

Net Interest Coverage (Annual)-5.08x

EPS Basic Excl Extra (Annual)$-3.76

P/FCF (TTM)21.52x

Receivables Turnover (TTM)2.75x

Total Debt / Equity (Quarterly)2.53x

EPS Incl Extra (TTM)$-3.79

Receivables Turnover (Annual)7.28x

ROI (TTM)-71.79%

P/S Ratio (TTM)4.02x

Pretax Margin (5Y Avg)-179.44%

Revenue / Share (Annual)$3.30

Tangible BV / Share (Annual)$11.92

Price vs S&P 500 (52W)-11.34%

Year-to-Date Return-32.92%

5-Day Price Return19.93%

EPS Normalized (Annual)$-3.76

ROA (5Y Avg)-31.92%

Net Profit Margin (Annual)-113.75%

Month-to-Date Return-0.31%

Cash Flow / Share (TTM)$-5.59

EBITD / Share (Annual)$-2.82

Operating Margin (Annual)-94.58%

LT Debt / Equity (Annual)1.43x

ROI (5Y Avg)-48.11%

LT Debt / Equity (Quarterly)2.16x

EPS Basic Excl Extra (TTM)$-3.79

P/TBV (Quarterly)2.36x

P/B Ratio (Annual)7.10x

Pretax Margin (TTM)-112.58%

Book Value / Share (Annual)$2.02

Price vs S&P 500 (13W)38.25%

Beta1.09x

P/FCF (Annual)5.21x

Revenue / Share (TTM)$3.29

ROE (TTM)-220.07%

52-Week Low$5.46

vGradeC

gGradeB

mGradeB

vgmGradeB

RGNX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$0.11	$0.43	+499.22%(+$0.54)
Q1 2026	May 14, 2026	-$1.41	-$1.72	-21.64%(-$0.31)
Q4 2025	Mar 5, 2026	-$0.84	-$1.30	-54.92%(-$0.46)
Q3 2025	Nov 6, 2025	-$1.30	-$1.20	+7.57%(+$0.10)
Q2 2025	Aug 7, 2025	-$1.05	-$1.38	-30.83%(-$0.33)

RGNX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.21

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
RGNXREGENXBIO Inc.	C	B	B	$9.66
AMGNAmgen Inc	C	C	B	$432.42
GILDGilead Sciences Inc	C	B	B	$145.68
ARGXargenx SE American Depositary Shares	D	A	B	$1023.21
MRNAModerna, Inc. Common Stock	D	C	A	$137.99
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$207.88
BIIBBiogen Inc. Common Stock	C	D	B	$218.50
BNTXBioNTech SE American Depositary Share	C	C	C	$102.08
NBIXNeurocrine Biosciences Inc	C	B	C	$154.06
EXELExelixis Inc	C	B	B	$54.45
HALOHalozyme Therapeutics, Inc.	C	B	B	$105.35
TECHBio-Techne Corp.	D	C	B	$72.35
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$351.46
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.97
RGENRepligen Corp	D	C	B	$176.27
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$118.15
PCVXVaxcyte, Inc. Common Stock	—	—	B	$59.84
QGENQIAGEN N.V.	C	C	B	$43.11
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$141.38
IBRXImmunityBio, Inc. Common Stock	F	A	B	$8.05
IMVTImmunovant, Inc. Common Stock	—	—	B	$41.20
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$57.80
CGONCG Oncology, Inc. Common stock	F	A	B	$74.34
CRSPCRISPR Therapeutics AG	D	B	C	$57.72
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	$18.77
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$25.19
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.00
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.01
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.76
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$29.32
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.82
KODKodiak Sciences Inc Common Stock	—	—	B	$37.72
MESOMesoblast Limited American Depositary Shares	D	B	B	$17.44
VCELVericel Corporation	D	B	B	$40.95
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$44.84
ADMAADMA Biologics, Inc.	C	C	C	$9.34
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$36.62
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$5.77
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.83
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	$123.41
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.34
ALVOAlvotech Ordinary Shares	C	D	C	$4.95
NVAXNovavax Inc	B	D	C	$9.26
MAZEMaze Therapeutics, Inc. Common Stock	—	—	C	$27.44
SLBTSL Science Holding Limited Ordinary Shares	—	—	C	$2.70
REPLReplimune Group, Inc.	—	—	A	$15.50
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.45
VORVor Biopharma Inc. Common Stock	—	—	B	$22.65
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$21.70
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	B	$13.82
SANASana Biotechnology, Inc. Common Stock	—	—	B	$3.93

About REGENXBIO Inc.

Regenxbio is a clinical-stage biotechnology company developing gene therapies using its proprietary NAV Technology Platform based on adeno-associated virus (AAV) vectors. The company targets retinal, neuromuscular, and neurodegenerative diseases by delivering genes to cells to correct genetic defects or enable therapeutic protein production. Its pipeline addresses unmet medical needs in genetic and degenerative disorders.